Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679802 | 1.00 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1596887 | 1.00 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL20570928 | 0.98 | POLB (0.41) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1597059 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1597060 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL3335647 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL11895384 | 0.92 | POLB (0.47) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL11896218 | 0.92 | POLB (0.47) | POLBL3MBTL1DPP4PREPFAP | |
| Tert-Butanol SCHEMBL28911378 | 0.91 | HTT (0.38) | POLBL3MBTL1DPP4NPC1RAB9A | |
| Tert-Butanol SCHEMBL28547075 | 0.85 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393918-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
| EP-1554254-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004041791-A1 | N-ARYL ACETYL CYCLIC AMINE DERIVATIVES AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041807-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004035548-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885DPP4 1301/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885DPP4 1301/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885DPP4 1301/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885DPP4 1301/4885 |
| US-20070105893-A1 | Novel Compounds | CNR1, CNR2, OPRL1 | POLB 4359/4885L3MBTL1 2949/4885DPP4 4839/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885DPP4 1301/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | POLB 3607/4885L3MBTL1 3402/4885DPP4 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.